Literature DB >> 18214137

[Recommendations for the use of voiding diaries and symptom or quality of life questionnaires in the investigation of non-neurological female urinary incontinence].

Loïc Le Normand1.   

Abstract

The use of a voiding diary is recommended for the evaluation of urinary incontinence. The use of a validated French symptom questionnaire is recommended to standardize the clinical interview and to define the type of urinary incontinence. Evaluation of the impact of incontinence by quality of life questionnaire is recommended. For use in routine clinical practice, questionnaires must comprise a limited number of questions so that they can be completed rapidly by the patient and easily interpreted by the therapist. In everyday practice, it is recommended to use the UPS self-administered questionnaire, otherwise the MHU urinary disability questionnaire, which must be combined with evaluation of the impact of incontinence on quality of life by using the visual analogue scale of question 5 of the ICIQ. Longer questionnaires specifically targeting the symptoms evaluated can be used in the field of research without neglecting symptoms that can be induced by treatment.

Entities:  

Mesh:

Year:  2007        PMID: 18214137

Source DB:  PubMed          Journal:  Prog Urol        ISSN: 1166-7087            Impact factor:   0.915


  2 in total

1.  A Multi-Center, Randomized, Blind, Controlled Clinical Trial of the Safety and Efficacy of Micro Radio Frequency Therapy System for the Treatment of Overactive Bladder.

Authors:  Zhi-Hui Xu; Peng-Fei Zhang; Yu-Feng Wang; Ao Ma; Yasmeen Bano; Alisherjon Ibrohimov; Chen Zhang; Hao-Fei Jiang; Yang Zhang; Yan-Lan Yu; Hai-Hong Jiang
Journal:  Front Med (Lausanne)       Date:  2022-05-12

2.  Sphingosine Kinase 1 urothelial expression is increased in patients with neurogenic detrusor overactivity.

Authors:  Quentin Ballouhey; Jalesh N Panicker; Catherine Mazerolles; Mathieu Roumiguie; Falek Zaidi; Pascal Rischmann; Bernard Malavaud; Xavier Game
Journal:  Int Braz J Urol       Date:  2015 Nov-Dec       Impact factor: 1.541

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.